CJC-1295 w\/ DAC 5MG, also known as DAC:GRF, is a synthetic peptide developed for controlled laboratory research. Researchers study this compound as an analog of growth hormone-releasing hormone (GHRH), also referred to as growth hormone-releasing factor (GRF). Because of its modified structure, this formulation supports research focused on extended peptide activity within non-clinical models.<\/p>\n
CJC-1295 w\/ DAC shares the same 29-amino acid peptide backbone as CJC-1295 without DAC. However, this version includes an added chemical modification known as the Drug Affinity Complex, or DAC. This modification plays a key role in how the peptide behaves in laboratory research settings.<\/p>\n
The Drug Affinity Complex allows CJC-1295 w\/ DAC to bind to serum albumin under research conditions. As a result, researchers observe prolonged peptide presence compared to non-DAC formulations. This extended interaction makes the compound useful in studies that examine peptide stability and sustained signaling behavior over time.<\/p>\n
Because of this property, laboratories often select DAC-modified peptides when research designs require longer observation windows. The DAC structure helps researchers reduce variability associated with rapid peptide breakdown during controlled experiments.<\/p>\n
In laboratory research, scientists use CJC-1295 w\/ DAC to study peptide signaling patterns and duration-related behavior within defined experimental systems. These studies often focus on how structural modifications influence peptide persistence rather than immediate response.<\/p>\n
Researchers value this compound because its extended activity supports research designs that rely on fewer preparation steps and more consistent experimental timing. As a result, laboratories can compare data across study cycles with improved clarity.<\/p>\n
CJC-1295 w\/ DAC 5MG is supplied as a lyophilized powder intended for laboratory preparation. Researchers reconstitute the material according to internal laboratory protocols prior to experimental use. This format supports compound stability and consistent handling across research workflows.<\/p>\n
By following standardized preparation methods, laboratories help maintain compound integrity and support repeatable experimental conditions.<\/p>\n
Laboratories store the lyophilized compound in a cool, dry place away from light to preserve stability. After reconstitution, researchers refrigerate the solution for short-term use. For longer-term storage, freezing at minus 20 degrees Celsius helps maintain material integrity.<\/p>\n
Proper storage supports consistent compound behavior throughout extended research periods.<\/p>\n
CJC-1295 w\/ DAC 5MG is intended strictly for scientific research use and is not for human or veterinary applications. Each batch meets pharmaceutical-grade quality standards to support reliable laboratory research.<\/p>\n
Independent testing and batch documentation allow researchers to review material specifications prior to use. This process supports clear data collection, structured analysis, and dependable research outcomes.<\/p>","protected":false},"excerpt":{"rendered":"
CJC-1295 w\/ DAC 5MG, also known as DAC:GRF, is a synthetic peptide developed for controlled laboratory research. Researchers study this compound to examine extended peptide activity and sustained signaling behavior enabled by its Drug Affinity Complex modification.<\/p>\n